Pattrapornpisut, P., Avila-Casado, C. & Reich, H. N. IgA nephropathy: core curriculum 2021. Am. J. Kidney Dis. 78, 429–441 (2021).

Article  CAS  PubMed  Google Scholar 

Berthoux, F. et al. Predicting the risk for dialysis or death in IgA nephropathy. J. Am. Soc. Nephrol. 22, 752–761 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Jarrick, S. et al. Mortality in IgA nephropathy: a nationwide population-based cohort study. J. Am. Soc. Nephrol. 30, 866–876 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Moriyama, T. et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS ONE 9, e91756 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Okonogi, H. et al. A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clin. Exp. Nephrol. 23, 16–25 (2019).

Article  CAS  PubMed  Google Scholar 

Suzuki, H. et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J. Clin. Invest. 118, 629–639 (2008).

CAS  PubMed  PubMed Central  Google Scholar 

Suzuki, H. et al. The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol. 22, 1795–1803 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xin, G. et al. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J. Nephrol. 26, 683–690 (2013).

Article  CAS  PubMed  Google Scholar 

Zhai, Y. L. et al. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine 95, e3099 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lafayette, R. et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402, 859–870 (2023).

Article  CAS  PubMed  Google Scholar 

Wheeler, D. C. et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 100, 215–224 (2021).

Article  CAS  PubMed  Google Scholar 

Heerspink, H. J. L. et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584–1594 (2023).

Article  CAS  PubMed  Google Scholar 

Rodrigues, J. C., Haas, M. & Reich, H. N. IgA nephropathy. Clin. J. Am. Soc. Nephrol. 12, 677–686 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie, Y. & Chen, X. Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am. J. Nephrol. 28, 1–7 (2008).

Article  PubMed  Google Scholar 

Schena, F. P. & Nistor, I. Epidemiology of IgA nephropathy: a global perspective. Semin. Nephrol. 38, 435–442 (2018).

Article  PubMed  Google Scholar 

Okpechi, I. G. et al. Epidemiology of histologically proven glomerulonephritis in Africa: a systematic review and meta-analysis. PLoS ONE 11, e0152203 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Nair, R. & Walker, P. D. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 69, 1455–1458 (2006).

Article  CAS  PubMed  Google Scholar 

Kiryluk, K., Novak, J. & Gharavi, A. G. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu. Rev. Med. 64, 339–356 (2013).

Article  CAS  PubMed  Google Scholar 

Sanchez-Rodriguez, E., Southard, C. T. & Kiryluk, K. GWAS-based discoveries in IgA nephropathy, membranous nephropathy, and steroid-sensitive nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 16, 458–466 (2021).

Article  CAS  PubMed  Google Scholar 

Feehally, J. et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J. Am. Soc. Nephrol. 21, 1791–1797 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gharavi, A. G. et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat. Genet. 43, 321–327 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kiryluk, K. & Novak, J. The genetics and immunobiology of IgA nephropathy. J. Clin. Invest. 124, 2325–2332 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kiryluk, K. et al. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat. Genet. 55, 1091–1105 (2023).

Article  CAS  PubMed  Google Scholar 

Magistroni, R., D’Agati, V. D., Appel, G. B. & Kiryluk, K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 88, 974–989 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai, K. N. et al. IgA nephropathy. Nat. Rev. Dis. Primers 2, 16001 (2016).

Article  PubMed  Google Scholar 

Shen, P. et al. Clinicopathological characteristics and outcome of adult patients with hematuria and/or proteinuria found during routine examination. Nephron Clin. Pract. 103, c149–c156 (2006).

Article  PubMed  Google Scholar 

Moldoveanu, Z. et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 71, 1148–1154 (2007).

Article  CAS  PubMed  Google Scholar 

Allen, A. C., Bailey, E. M., Barratt, J., Buck, K. S. & Feehally, J. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J. Am. Soc. Nephrol. 10, 1763–1771 (1999).

Article  CAS  PubMed  Google Scholar 

Hiki, Y. et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 59, 1077–1085 (2001).

Article  CAS  PubMed  Google Scholar 

Xu, L. X. & Zhao, M. H. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int. 68, 167–172 (2005).

Article  CAS  PubMed  Google Scholar 

Barratt, J., Smith, A. C. & Feehally, J. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology 12, 275–284 (2007).

Article  CAS  PubMed  Google Scholar 

Dotz, V. et al. O- and N-glycosylation of serum immunoglobulin A is associated with IgA nephropathy and glomerular function. J. Am. Soc. Nephrol. 32, 2455–2465 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohyama, Y., Renfrow, M. B., Novak, J. & Takahashi, K. Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don’t know. J. Clin. Med. 10, 3467 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gesualdo, L., Di Leo, V. & Coppo, R. The mucosal immune system and IgA nephropathy. Semin. Immunopathol. 43, 657–668 (2021). A very good review of the role of the mucosal immune system in IgAN.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Franc, V. et al. Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing. J. Proteom. 92, 299–312 (2013).

Article  CAS  Google Scholar 

Yamada, K. et al. Down-regulation of core 1 β1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol. Dial. Transpl. 25, 3890–3897 (2010).

Article  CAS  Google Scholar 

Suzuki, H. et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J. Biol. Chem. 289, 5330–5339 (2014).

Article  CAS  PubMed  Google Scholar 

Xing, Y. et al. C1GALT1